New Pill-Infusion combo takes on Hard-to-Treat cancers
Disease control
Ongoing
This study tests a new oral drug called C019199 combined with an immunotherapy drug, sintilimab, in people with advanced solid tumors that no longer respond to standard treatments. The trial involves 155 participants and aims to check safety, find the right dose, and see if the c…
Phase: PHASE1, PHASE2 • Sponsor: Fujian Haixi Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC